Ulla Wilking

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression

Linda S. Lindström, Eva Karlsson, Ulla Wilking et al. · Journal of Clinical Oncology · 2012 · 517 citations

Hormonal Receptors, Breast Oncology, Progesterone Receptor +15

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

Ulla Wilking, Eva Karlsson, Lambert Skoog et al. · Breast Cancer Research and Treatment · 2010 · 118 citations · Full text

Her2 Status, Breast Oncology, Cancer Epidemiology +7

Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting

Sara Olofsson, Hanna Norrlid, Eva Karlsson et al. · The Breast · 2016 · 45 citations · Full text

Discordance in hormone receptor status in breast cancer during tumor progression.

Emelié Karlsson, Leena Lindström, Ulla Wilking et al. · Journal of Clinical Oncology · 2010 · 41 citations

Hormone Receptor Status, Relapse Tumor, Breast Oncology +19

Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden

Ulla Wilking, Bengt Jönsson, Nils Wilking et al. · Acta Oncologica · 2010 · 13 citations · Full text